Dabigatran, Rivaroxaban and Apixaban versus Enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: Pool-analysis of phase III randomized clinical trials
- 31 August 2012
- journal article
- research article
- Published by Elsevier BV in Thrombosis Research
- Vol. 130 (2), 183-191
- https://doi.org/10.1016/j.thromres.2012.02.011
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II)Thrombosis and Haemostasis, 2011
- Apixaban versus Enoxaparin for Thromboprophylaxis after Hip ReplacementNew England Journal of Medicine, 2010
- Rivaroxaban vs Dabigatran for Thromboprophylaxis After Joint-replacement Surgery: Exploratory Indirect Comparison Based on Meta-Analysis of Pivotal Clinical TrialsCroatian Medical Journal, 2010
- Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical developmentThrombosis and Haemostasis, 2010
- Apixaban or Enoxaparin for Thromboprophylaxis after Knee ReplacementNew England Journal of Medicine, 2009
- State-of-the-Art Review: Assessing the Safety Profiles of New Anticoagulants for Major Orthopedic Surgery ThromboprophylaxisClinical and Applied Thrombosis/hemostasis, 2009
- Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplastyThrombosis and Haemostasis, 2009
- Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacementThrombosis and Haemostasis, 2008
- Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trialJournal of Thrombosis and Haemostasis, 2007
- BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging studyJournal of Thrombosis and Haemostasis, 2005